BPC-157 peptide use rises despite lack of FDA approval

The use of the experimental peptide BPC-157 is increasing in the United States, particularly among white males, according to an analysis of electronic health records. While some peptides like insulin have received FDA approval, BPC-157 has not undergone human clinical trials to establish its safety or efficacy.

Online wellness and longevity influencers have popularized the compound, promoting it as a remedy for muscle injuries, gut issues, and various other health conditions. Some users have reported adverse effects, including prolonged fatigue, anxiety, and involuntary muscle or eye twitching.

While preclinical studies in mice suggest the peptide may aid muscle healing and promote angiogenesis, medical experts warn that these results do not necessarily translate to humans. Currently, the substance is often sold by vendors claiming it is intended only for laboratory research and not for human consumption.